Endometrial cancer is no longer staged and treated on anatomy and histology alone. A three-test molecular panel — POLE sequencing, mismatch repair (MMR) immunohistochemistry and p53 immunohistochemistry — sorts every tumour into one of four types, and the type can change the risk group, the FIGO stage, and the radiotherapy decision.
The four molecular types
POLEmut — polymerase epsilon ultramutated (about 5–10%)
- Pathogenic POLE exonuclease-domain mutation → ultramutated tumour
- Often looks high-grade under the microscope, behaves indolently — very high neoantigen load, strong immune response
- Best prognosis of the four types
MMRd — mismatch repair deficient (about 25–30%)
- Loss of MLH1, MSH2, MSH6 or PMS2 — sporadic MLH1 methylation, or germline Lynch syndrome
- Hypermutated; intermediate prognosis
- The immunotherapy-responsive type in advanced disease
- Every MMRd result → Lynch pathway: germline testing and cascade screening
NSMP — no specific molecular profile (about 40–50%)
- Copy-number-low remainder; mostly endometrioid
- The most heterogeneous group — the 2025 guidelines split it by grade and oestrogen receptor (ER) status
- Low-grade ER-positive → favourable end · High-grade or ER-negative → behaves as high-risk
- CTNNB1 mutation and L1CAM overexpression mark the worse end (used in the PORTEC-4a profile)
p53abn — p53 abnormal (about 15–25%)
- Copy-number-high group — almost all serous carcinomas, plus about a quarter of high-grade endometrioid cancers
- Worst prognosis; failure is predominantly distant
- Test HER2 — a subset is HER2-amplified and trastuzumab-responsive in advanced disease
Multiple-classifier tumours (~3–5%)
- Carry more than one classifying feature — classify by the driver
- POLEmut or MMRd with secondary abnormal p53 staining behaves as POLEmut/MMRd, not p53abn — do not escalate on the p53 result alone
How the molecular type moves the risk group
- Stage I–II POLEmut → low risk, whatever the grade or histotype — FIGO 2023 stage IAm POLEmut
- p53abn with myometrial invasion → high risk, even confined to the uterus — FIGO 2023 stage IICm p53abn
- MMRd and NSMP → allocated by stage, grade, LVSI — and, for NSMP, ER status
- Worked example: one stage IB, grade 3 endometrioid cancer — POLEmut = low risk (no adjuvant treatment) · NSMP = high-intermediate · p53abn = high risk (chemoradiation). Same stage, same grade — three different treatments.
Implications for radiotherapy
- POLEmut, stage I–II → omit adjuvant treatment. 97–100% recurrence-free survival in both PORTEC-3 arms — chemotherapy and radiotherapy added nothing measurable. De-escalation here is evidence-based, not undertreatment. (Stage III POLEmut: data thin; RAINBO-BLUE is testing omission.)
- Low risk (any type) → no adjuvant radiotherapy.
- Intermediate risk → vaginal brachytherapy (e.g. HDR 21 Gy in 3 fractions), or observation in selected patients. Pelvic EBRT is overtreatment at this level of risk.
High-intermediate risk → the molecular-integrated profile decides (PORTEC-4a, 569 women):
- Favourable (POLEmut, or NSMP CTNNB1 wild-type) → observation
- Intermediate (MMRd, or NSMP CTNNB1-mutant) → vaginal brachytherapy
- Unfavourable (p53abn, substantial LVSI, or L1CAM overexpression) → pelvic EBRT
- Vaginal recurrence 4.5% vs 1.6% vs standard brachytherapy — within the trial’s non-inferiority conclusion; no significant difference in recurrence-free or overall survival
- High risk, especially p53abn → chemoradiation, not radiotherapy alone (PORTEC-3) — see the tiles below
- MMRd → chemotherapy added nothing (5-year RFS 68% chemoradiation vs 76% radiotherapy alone). The systemic lever for MMRd is immunotherapy; radiotherapy decisions rest on stage and LVSI.
- NSMP → in between. A non-significant trend favouring chemoradiation, which the 10-year PORTEC-3 analysis suggests is modulated by ER status.
Practical points
- Order all three tests at diagnosis (POLE sequencing covering the 11 pathogenic exonuclease-domain variants, MMR IHC, p53 IHC). The 2025 guidelines allow POLE testing to be omitted only in low-risk stage I disease where the result could not change the adjuvant decision.
- Report the FIGO 2023 stage with the molecular annotation (m) — IAm POLEmut and IICm p53abn are staging categories in their own right.
- MMRd → Lynch pathway; p53abn/serous → HER2 testing.
- Counselling point for de-escalation: in PORTEC-4a, the small excess of vaginal recurrences in untreated favourable-profile patients were mostly isolated vault recurrences, which are usually salvageable.
- Fertility-sparing and ovarian-preservation decisions are also refined by molecular type in the 2025 guidelines — see the guideline algorithms.
Where this is heading: the RAINBO programme
Four international trials testing class-directed adjuvant treatment in high-risk endometrial cancer (results expected from 2028):
- p53abn-RED: chemoradiation + 2 years of olaparib vs chemoradiation alone
- MMRd-GREEN: radiotherapy + concurrent and adjuvant durvalumab (1 year) vs radiotherapy alone
- NSMP-ORANGE: radiotherapy + 2 years of progestin vs chemoradiation (ER-positive disease — a de-escalation question)
- POLEmut-BLUE: phase II de-escalation — no adjuvant therapy for lower-risk, none or radiotherapy alone for higher-risk POLEmut disease
References
- Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73.
- León-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020;38:3388–3397. doi:10.1200/JCO.20.00549
- PORTEC-3 investigators. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular class. Lancet Oncol 2025;26(10).
- van den Heerik ASVM, et al. Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): a randomised, phase 3, non-inferiority trial. Lancet Oncol 2026;27(1):23–35.
- Concin N, et al. ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma — update 2025. Lancet Oncol 2025;26:e423–e435.
- Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162:383–394.
- RAINBO research programme (Refining Adjuvant treatment IN endometrial cancer Based On molecular profile). ClinicalTrials.gov NCT05255653.
Summary prepared for clinician readers; not a substitute for the full guidelines or multidisciplinary discussion.